Each year, HOPA members elect the association’s new leadership who will provide crucial guidance in reaching HOPA’s strategic goals. Submitting your vote will directly impact the direction of HOPA as a leading voice for hematology/oncology pharmacy for years to come. We encourage all Lifetime, Full, and Technician members to please cast your vote.
Learn More About the Candidates
Larry Buie, PharmD BCOP FASHP
Clinical Pharmacy Manager, Lymphoma and BMT
Memorial Sloan Kettering Cancer Center
New York, NY
Residency Program Director, PGY2 Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
For the last three years, I have had the tremendous honor to serve the HOPA membership as an At-Large Member of the HOPA Board of Directors. Our organization is strong and we have advanced the oncology pharmacy profession by working together, building relationships, and expanding our reach to be more inclusive.
Our tag line is “Pharmacists Optimizing Cancer Care.” As President-Elect, I will continue to support our vision -- that all patients affected by cancer will have a hematology/oncology pharmacist as an integral member of their care team. The roles of the “oncology pharmacist” and the definition of the “care team” continue to change. HOPA must lead the development of the education, tools and resources required to meet the evolving needs of ALL pharmacists that provide cancer care. To accomplish this, I will work with the Board of Directors to:
- ensure increased opportunities for professional development
- continue to offer high quality education, with new opportunities for BCOP credit
- embrace new and innovative technologies for education delivery
- promote pharmacist-initiated research initiatives
- make HOPA a more patient-facing organization
- expand HOPA on a global scale, supporting oncology pharmacists around the world
- advocate for our cancer patients and the pharmacy profession
I am humbled and honored by the nomination for President-Elect and regardless of the election outcome, I will continue to advocate on behalf of our profession and our patients. Thank you for your consideration and the opportunity to serve you.
Lisa Davis, PharmD BCOP BCPS
Clinical Pharmacist, Oncology and Early Phase Clinical Trial Program
Medical Center and University of Arizona Cancer Center
Affiliate Member, Cancer Prevention and Control Program
University of Arizona Cancer Center
Professor | Pharmacy Practice & Science, College of Pharmacy University of Arizona
Adjunct Assistant Professor of Medicine | Division of Hematology-Oncology, Department of Medicine
University of Pennsylvania
It is an honor to be considered for the position of At-large Member of the Board of Directors and I am excited about the possibility of helping to promote and advance hematology/oncology pharmacy to optimize our patients’ care through this role. This goal has been foremost throughout my career, although my roles, responsibilities and activities have continually evolved. Because of this, I understand and appreciate the value – and necessity – of professional resources and tools that help one successfully change practice settings, pursue different areas of research, assume administrative responsibilities, and gain knowledge about the latest developments in hematology and oncology. HOPA has been the primary source of those resources and tools, as well as the hub for networking, collaborations, and collegial support. I would like to see HOPA further collaborative research that supports professional practices and engages members who are eager to contribute to these activities, and I have the skills to help lead these initiatives. HOPA provides professional development opportunities that are critical toward enhancing members’ roles in leadership, research, and advocacy. My perspective as an educator, researcher, and provider in the direct care of patients with cancer has provided me with firsthand knowledge of the many opportunities and challenges that we face in oncology, although most important, what our patients and their families face. Their strength and resilience fuels my motivation to help achieve the goals outlined in the HOPA strategic plan to address these and future challenges.
Becky Fahrenbruch, PharmD BCOP
Medical Science Liaison, Hematology Myeloid Team
I am honored to have been nominated for At-large board member and look forward to continuing my service to HOPA. I have been a member of HOPA since 2004 and have enjoyed working on the Needs Assessment and Standards Committees. Demonstrating my commitment, I was invited to serve as the Leadership Development Subcommittee Vice-Chair and am currently the Chair. These experiences have allowed me to be involved in projects such as the Dose Rounding Position Statement initiative/publication and development of the HOPA Pilot Mentoring Program.
HOPA is your organization. We should continue to focus on what the organization should be doing to help our hematology/oncology pharmacists and staff. I will listen to your ideas and am excited to hear your needs to improve patient care. With 20 years of professional experience, I represent many different aspects of oncology pharmacy practice including inpatient, outpatient, oral oncology, residency director, industry and management. I will bring ideas forward to implement and develop tools and programs to help further your professional career. My passions include mentoring, education, training and resource development. One of my top priorities is to continue to develop a mentorship program for all HOPA members. HOPA is working on a new Strategic Plan and I will work hard to achieve the goals and initiatives of the organization to improve the care of our cancer patients.
Bernadette Heron, PharmD BCOP
National PBM Clinical Pharmacy Program Manager
Department of Veterans Affairs
Since entering the field of hematology/oncology pharmacy, change has been continuous, but HOPA has remained the one constant in my profession. HOPA has kept its pulse on the profession, making it a resource like no other. I have had the pleasure to watch the organization grow from a few members to what it is today. It is with great pride that I accept the nomination and candidacy for the position of At-Large Board Member.
As an At-Large Board Member, my focus would be to help support the many talented members already engaged in the development of our core areas of professional development, professional resources, tools/research and advocacy.
HOPA has provided opportunities that has helped me to grow in areas outside of my comfort zone. I also want to encourage the membership to realize their potential within HOPA. Providing new ideas can help to expand our core areas, which can ultimately impact more patients.
Only with creative ideas taking us outside-of-the-box, will we be able to become an integral member of the hematology/oncology care team and touch the lives of every patient with cancer.
Emily Mackler, PharmD BCOP
Director, Clinical Quality Initiatives
Michigan Oncology Quality Consortium (MOQC)
Ann Arbor, MI
I am honored to be considered for the HOPA Board of Directors At-Large Director position. I have been a member of HOPA for over 10 years. I have previously been a member of the BCOP Recertification Committee, Chair of the Oral Chemotherapy Task Force, and Chair of the Quality Oversight Task Force. Currently, I am the inaugural Chair of the Quality Oversight Committee and HOPA’s liaison to the National Quality Forum.
As my own position and scope of practice has evolved from clinical practice at an academic medical center to leading state-wide oncology quality efforts among community and academic practices, so has my lens regarding the incredible opportunity HOPA has to support its members in providing excellent care to the patients with cancer they serve. Through multiple roles, I have had a unique opportunity to advocate for oncology pharmacists, oncology patients and our Association. If elected, I would work with the HOPA Board of Directors and members to strengthen our roles within the healthcare system by highlighting the high quality of care we provide and the contributions towards positive patient outcomes of oncology pharmacy practice. This goal can be accomplished by continuing to provide premier education and practice standards as well as expanding on the collaborative efforts of our organization in providing real world outcomes to key stakeholders.
I am grateful for the opportunity I have to support this wonderful organization. Thank you for the consideration of your vote.